Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

MDbio Starts Clinical Trials for Pharmaceutical-Grade Products That Target Sleeplessness, Stress and Pain

By: Magic PR

Today, MDbio, in conjunction with their research partners at Radicle Science, are announcing the start of three separate clinical trial studies which will assess the efficacy of individual products that target sleeplessness, pain and stress. The purpose of the clinical trials is to understand the efficacy of three new plant-based MDbio products. During the trials, the doctors will test synergistic outcomes in multi-active formula compounds and determine the effects of drug holidays using plant-based medicines. MDbio will test their current lineup of products; MDsleep™, MDrelief™ and MDcalm™ on over 2,500 US adults. The trials will last 4 weeks, with the first trial beginning in August.  All three products have already successfully gone through extensive internal observational trials, partially testing on patients from their own practices suffering from the corresponding condition.

“We are excited to team up with Dr. Chen and his colleagues in obtaining large scale efficacy trial data on our current portfolio of products. Their team embodies our commitment in developing prodicts that are derived from real scientific outcomes and working together with our patients and customers to always refine and better our product offering. Today continues our investment in developing medicines that are safe and effective.” said Brenden Dougherty, Chief Executive at MDbio.

The results from the highly anticipated clinical trials are likely to be available to the public in Q1 of 2023. MDbio currently  sells all three products for purchase on their website.

MDbio is a leading plant-based medicine company that sells safe, pharmaceutical-grade products. Founded by four award winning medical doctors with notable and successful careers at premier American hospitals and medical centers. MDbio develops products that restore balance (homeostasis) to the body during times of sleeplessness, anxiety, pain and other common situations. Our doctors seek to restore not only wellness to patients, but a true “joy of living” by seeking out, testing and refining natural ingredients that support good health. Learn more at www.mdbiowellness.com.

Radicle Science is an AI-driven healthtech B-corp offering the first ever scalable path to validate and predict the effects of health and wellness products, transforming them into democratized precision solutions for ailments or enhancement of human function. Radicle Science leverages a proprietary data analytics platform and a virtual, direct-to-consumer (D2C) clinical trial model to deliver objective health outcome data across diverse populations and conditions—all at a fraction of the cost and time of traditional methods. The Radicle Vision is a future where affordable, accessible health and wellness products are trusted by patients, recommended by healthcare providers, reimbursed by insurance and used as widely as pharmaceutical drugs. Learn more at www.RadicleScience.com.

What consumers can expect to gain from three new plant-based medicines

MDbio founders have become renowned for their use of plant-based compounds to create successful medicines. During their combined 80 years of service within healthcare, the founders of MDbio found it increasingly clear that drugs prescribed to alleviate conditions regarding sleep, anxiety and pain were a double edged sword. Although these drugs were effective, they can also be toxic, harmful or addictive for patients.

After many years of utilizing plant-based compounds, MDbio concluded that plant-based medicines, including phytocannabinoids, offer patients real benefits without appreciable side effects. These medicines had undeniable potential to help reduce suffering and improve patient outcomes.

These medicines will be backed up by vigorous testing and trial data and provide patients with plant-based alternatives that can restore balance (homeostasis) to the body during times of sleeplessness, anxiety, pain and other common situations.

Taking learnings and experience and providing resources for a digital-first world:

While the results of the clinical trials for these three new plant-based medicines are highly anticipated, MDbio and their specialist team are not resting on their laurels. They recently launched their Doctor’s Desk (Resource Center), which has ample free information and inspiration for better mind and body nourishment.

For additional information please contact MDbio directly at hello@mdbiowellness.com or 800-447-1485.

Source: https://thenewsfront.com/mdbio-starts-clinical-trials-for-pharmaceutical-grade-products-that-target-sleeplessness-stress-and-pain/

About MDbio Wellness

MDbio provides medical-grade, patient-tested Full Spectrum Hemp and plant-based wellness products that are unique in the industry for their innovation, quality, potency, and safety.

Contact MDbio Wellness


Los Angeles
CA
United States

Website: https://www.mdbiowellness.com/


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.